The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recurring fever?

England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

Please provide your email address to receive an email when new articles are posted on . A phase 2 study included 129 individuals with MS randomized to receive frexalimab or placebo for 24 weeks.

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...

Relapsing polychondritis is a rare degenerative condition with no cure. Treatment typically focuses on addressing symptoms and slowing the progression of the condition. Relapsing polychondritis is a ...